IMMUNEERING CORPORATION - ATEBIMETINIB PLUS MGNP SHOWS LONG SURVIVAL AND OUTSTANDING TOLERABILITY IN PHASE 2 PANCREATIC CANCER

Reuters · 2d ago

Please log in to view news